A single 1000 mg infusion of iron isomaltoside 1000 demonstrates a more rapid hemoglobin response and reduced risk of cardio-vascular adverse events compared to multiple doses of iv iron sucrose in the ferwon trials

Authors
Category Primary study
JournalNephrology Dialysis Transplantation
Year 2019
This article has no abstract
Epistemonikos ID: 34dc3958ef6a0dd7c1687e257347270c9a265c9c
First added on: Feb 11, 2025